aducanumab
Selected indexed studies
- Aducanumab. (, 2012) [PMID:34251780]
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. (J Prev Alzheimers Dis, 2022) [PMID:35542991]
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. (Ageing Res Rev, 2024) [PMID:38253184]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Aducanumab. (2012) pubmed
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. (2022) pubmed
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. (2024) pubmed
- Aducanumab for the treatment of Alzheimer's disease: a systematic review. (2023) pubmed
- The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. (2016) pubmed
- Aducanumab. (2006) pubmed
- Aducanumab: First Approval. (2021) pubmed
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. (2022) pubmed
- Aducanumab-Hope or Disappointment for Alzheimer's Disease. (2023) pubmed
- Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. (2023) pubmed